| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PI |
| Uniprot No | P01009 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-418aa |
| 氨基酸序列 | MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK |
| 预测分子量 | 46,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PI重组蛋白的模拟参考文献示例(仅供参考，非真实文献)：
1. **《重组人PI3K蛋白的表达及其激酶活性分析》**
作者：Zhang, L. et al.
摘要：本研究成功在大肠杆菌中表达了具有生物活性的重组人PI3K蛋白，并通过Ni柱亲和层析纯化。体外激酶实验证实该蛋白可催化PIP2生成PIP3.为PI3K-Akt信号通路研究提供工具。
2. **《蛋白酶抑制剂重组蛋白的制备与抗病毒效应研究》**
作者：Wang, Y. et al.
摘要：利用昆虫细胞表达系统制备重组PI(蛋白酶抑制剂)蛋白，并验证其抑制HIV-1蛋白酶活性的能力。实验显示该蛋白可显著降低病毒复制效率，提示其在抗病毒治疗中的潜力。
3. **《基于重组PI蛋白的肿瘤靶向药物递送系统开发》**
作者：Chen, H. et al.
摘要：通过融合肿瘤靶向肽与重组PI蛋白，构建了新型纳米载药系统。体外实验表明该系统能特异性识别肿瘤细胞并增强药物胞内释放，为精准治疗提供新策略。
4. **《植物来源PI重组蛋白的抗氧化功能评价》**
作者：Kim, S. et al.
摘要：从马铃薯中克隆PI基因并在毕赤酵母中表达，纯化后的重组蛋白表现出强抗氧化活性，可清除自由基并延缓细胞氧化损伤，或应用于食品与医药领域。
注：以上文献为示例性质，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
**Background of Recombinant PI Proteins**
Recombinant PI (Protease Inhibitor or Phosphatidylinositol-interacting) proteins are engineered molecules designed to mimic naturally occurring proteins involved in critical cellular processes. These proteins are produced using recombinant DNA technology, where target genes are cloned into expression vectors and expressed in host systems like *E. coli*, yeast, or mammalian cells. PI proteins often play roles in signaling pathways, membrane trafficking, or immune regulation. For instance, Phosphatidylinositol-binding proteins are essential in lipid signaling, modulating processes such as vesicle formation and cell proliferation. Alternatively, protease inhibitor variants (e.g., SARS-CoV-2 PLpro inhibitors) are studied for their ability to block viral protease activity, offering therapeutic potential.
The development of recombinant PI proteins addresses challenges in studying native proteins, which may be low in abundance or difficult to purify. Recombinant versions provide high purity, scalability, and customization (e.g., tagging for detection). However, structural complexity, post-translational modifications, or solubility issues may necessitate optimized expression systems. For example, mammalian systems are preferred for PI proteins requiring glycosylation.
Applications span biomedical research, drug discovery, and diagnostics. Recombinant PI proteins serve as tools to study protein-lipid interactions, screen antiviral compounds, or develop targeted therapies. In therapeutics, they may act as biologics to regulate aberrant signaling in cancer or autoimmune diseases. Despite progress, challenges remain in maintaining functional conformations and minimizing immunogenicity in clinical settings.
Overall, recombinant PI proteins represent a versatile platform bridging structural biology and translational medicine, with ongoing advancements in bioprocessing enhancing their utility across diverse fields.
×
